Health Care/Hospital
Leading New Zealand cancer research 'super-charged' by data privacy startup
DUNEDIN, New Zealand, May 25, 2023 /PRNewswire/ -- Two top medical research and biotech innovators today announce a partnership that will supercharge cancer research while providing new levels of health data privacy. Amaroq Therapeutics, a world-leading company based in New Zealand focused on de...
2023-05-25 21:00
2027
Tantech's Successful Exhibition in the NRA Show Increased Brand Visibility Within Industry
LISHUI, China, May 25, 2023 /PRNewswire/ -- Tantech Holdings Ltd (NASDAQ: TANH) ("Tantech" or the "Company") today announced that its subsidiary, EPakia Inc., made a successful presentation at the 2023 National Restaurant Association (NRA) Show. The NRA Show is sponsored by the National Restaura...
2023-05-25 20:30
3552
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders * Phase 1 clinical trial is ex...
2023-05-25 19:00
2371
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey MELBOURNE, Australia and INDIANAPOLIS, May 2...
2023-05-25 19:00
2015
111 to Announce First Quarter 2023 Unaudited Financial Results on June 15, 2023 - Conference Call to Follow
SHANGHAI, May 25, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2023-05-25 14:05
1978
TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I
SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial inAustralia. The trial will be a randomized, double-b...
2023-05-25 09:51
2032
Clarity's theranostic prostate cancer trial advances to cohort 2
Highlights * Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. * No dose limiting toxicities (DLTs) have been reported in cohort 1. * The Sa...
2023-05-24 21:03
2723
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812,a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment o...
2023-05-24 16:14
1969
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (Investigational New Drug) approval from the Korean MFDS (Mi...
2023-05-23 20:00
1766
SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum
* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...
2023-05-23 20:00
2085
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., May 23, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a clinical-stage biopharmaceutical company focusing on oncology and autoimmune diseases, today announced that the phase1a trial of MHB018A has commenced with the dosing of its first subje...
2023-05-23 19:00
4908
Introducing Ceretone's Core One: The Revolutionary OTC Hearing Aid Launching on Indiegogo in May
ONTARIO, Calif., May 23, 2023 /PRNewswire/ -- Ceretone, the audiology technology innovator, is excited to announce that its latest product, the Core One, will be launched on Indiegogo onMay 30, 2023. The Core One is set to be the smallest over-the-counter (OTC) hearing aid on the market, providin...
2023-05-23 18:01
1889
OMRON Healthcare Celebrates 50 Years of Blood Pressure Monitor History
KYOTO, Japan, May 23, 2023 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (hereinafter referred to as the Company) based in Muko City,Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year. Since the introduction of its fir...
2023-05-23 14:00
1938
Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics
CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), today announced it has entered into an agreement with Mo...
2023-05-23 13:00
1705
Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma
ALAMEDA, Calif. and TAIPEI, May 22, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform to address gaps in cancer care, today announced that the first patient has been dosed with AC...
2023-05-23 00:00
2154
HanX Biopharmaceuticals announces HX009 IND approval from FDA
WUHAN, China, May 22, 2023 /PRNewswire/ -- Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients w...
2023-05-22 22:00
1966
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced thatthe International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facili...
2023-05-22 16:30
2535
Xinhua Silk Road: Conference held to foster digital, AI-driven life and health industry development in Wuxi, E. China
BEIJING, May 22, 2023 /PRNewswire/ -- The 2023 Taihu Bay Future Healthcare
Conference (2023 TBHC) was held on Thursday in Wuxi City in eastChina's Jiangsu
Province to better integrate with digitalization and artificial intelligence
(AI) to enable local life and health industry development.
2023-05-22 16:06
1810
Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102
SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug ...
2023-05-21 22:23
2270
EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter
SINGAPORE, May 19, 2023 /PRNewswire/ -- EUDA Health Holdings Limited (the "Company" or "EUDA") (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notifica...
2023-05-20 04:05
5699
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685